What type of study is this?

September 10, 2025Alimentary Pharmacology & TherapeuticsOpen Access

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

View Full Paper

Ask AI

Bookmark

Authors

DYDorothy Cheuk‐Yan YiuChinese University of Hong Kong JLJimmy Che‐To LaiChinese University of Hong Kong LCLandon L. ChanChinese University of Hong Kong

Discussion

Member takes

Implication

Observational analysis finds low HBV reactivation in liver cancer patients on immune checkpoint inhibitors, suggesting safety of ICI with antiviral prophylaxis.

Key Points

The absolute risk of HBV reactivation is low among liver cancer patients receiving immune checkpoint inhibitors.
Among 1596 patients with current or past HBV infection, only 25 (1.6%) experienced reactivation during treatment.
Patients receiving antiviral prophylaxis experienced a significantly lower HBV reactivation rate of 1.4% compared to 3.7% without it.
Use of immune checkpoint inhibitors does not increase the risk of HBV reactivation compared to tyrosine kinase inhibitors.

Cite This Study

Yiu et al. (2025) studied this question.

synapsesocial.com/papers/68c193e99b7b07f3a0617b91 https://doi.org/10.1111/apt.70367

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis finds low HBV reactivation in liver cancer patients on immune checkpoint inhibitors, suggesting safety of ICI with antiviral prophylaxis.

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider